Abstract:Background: Aspirin has been widely used as treatment for inflammation, pain and cardiovascular events, and recently some studies found that patients of cancer with aspirin use seemed to have longer survival. However, the supporting data varied, and the arguments existed among studies. To better understand this issue, we conducted this systematic review and meta-analysis to investigate whether patients of cancer with aspirin use had longer survival. Methods: This study has been registered in PROSPERO (No· CRD42018102280). We searched the PubMed, Web of Science and Embase for studies about aspirin use and survival of cancer published before May 2018, and the references of related studies were also reviewed. The primary outcomes were cancer-specific survival and overall survival for patients of cancer. In meta-analysis, pooled odds ratios (OR) and 95% confidence intervals (CI) were estimated with random-effects or fixed-effects model according to the heterogeneity which was estimated by Q statistic. Subgroup analysis was performed to identify the associations between aspirin use and survival of different kinds of cancers, and the influences of prediagnosis or postdiagnosis aspirin use and duration of aspirin use were also assessed. For colorectal cancer, we specially assessed the influence of PIK3CA mutation status and prostaglandin-endoperoxide synthase 2 (PTGS2) expression in this study. Findings: Totally 57 observational studies with 17 kinds of cancers and 1274 933 participants were included. Compared with aspirin nonusers, patients of cancer with postdiagnosis aspirin use had both prolonged cancer-specific survival (OR 0·86; 95% CI 0·72-0·99; P heterogeneity <0·001) and overall survival (OR 0·81; 95% CI 0·67-0·95; P heterogeneity <0·001), while prediagnosis aspirin use showed no significant associations. Subgroup analysis indicated that patients of colorectal cancer with aspirin use had significantly improved cancer-specific survival (OR 0·81; 95% CI 0·68-0·95) and overall survival (OR 0·78; 95% CI 0·66-0·90) when compared with aspirin nonusers, while patients of oesophageal cancer showed improved overall survival (OR 0·63; 95% CI 0·31-0·94), and patients of breast cancer showed improved cancer-specific survival (OR 0·83; 95% CI 0·68-0·98). The duration-response analysis showed that only patients with aspirin use ≥ 5 years had prolonged cancer-specific survival (OR 0·82; 95% CI 0·70-0·94), while patients with aspirin use < 2·5 years or < 5 years didn't have significant results. For patients of colorectal cancer with aspirin use, specially we found that compared with aspirin nonusers, those with PIK3CA mutation had both improved cancer-specific survival (OR 0·33; 95% CI 0·11-0·55) and overall survival (OR 0·67; 95% CI 0·44-0·90), and those with high or positive PTGS2 expression was associated with prolonged overall survival (OR 0·65; 95% CI 0·50-0·80). Interpretation: Our study suggested that not all patients of cancer with aspirin use, but those with postdiagnosis aspirin use might have longer survival, and only when aspirin use at least 5 years were associated with improved survival. We also found that patients of oesophageal cancer, breast cancer, and specially patients of colorectal cancer with PIK3CA mutation or high PTGS2 expression, could have more survival benefits with aspirin use. Trial Registry: This study has been registered in PROSPERO (No· CRD42018102280). Funding: This work was supported by National Natural Science Foundation of China (No·30901427). Declaration of Interest: We declare no competing interests.

Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis

Relationship Between Aspirin Use after Diagnosis of Colorectal Cancer and Patient Survival: a Meta-Analysis of Observational Studies

Aspirin Use Improves Survival after Cancer Diagnosis: A Systematic Review and Meta-Analysis of Fifty-Seven Studies

Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis

Timing of Aspirin Use among Patients with Colorectal Cancer in Relation to Mortality: A Systematic Review and Meta-Analysis

Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (programmed Cell Death 1 Ligand 1) Expression Status.

Low‐dose aspirin use and colorectal cancer survival in 32,195 patients—A national cohort study

Aspirin Use and Common Cancer Risk: A Meta-Analysis of Cohort Studies and Randomized Controlled Trials

Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 pathway.

Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies

Aspirin and Cancer Survival: An Analysis of Molecular Mechanisms

Effect of Long Term Prediagnostic Aspirin Intake on the Prognosis of Esophageal Squamous Cell Carcinoma Receiving Radical Surgery

Aspirin Use and the Risk of Gastric Cancer: A Meta-Analysis

Association of prophylactic low-dose aspirin use with all-cause and cause-specific mortality in cancer patients

Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study

Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis

Aspirin or statin use in relation to survival after surgery for esophageal cancer: a population-based cohort study

Aspirin and Colorectal Cancer: Back to the Future

Benefit and Harm of Aspirin on Mortality From Gastrointestinal Cancers Vs Bleeding in Helicobacter pylori-Eradicated Patients

Exploring the Protective Role of Aspirin Use in Mitigating Colorectal Cancer (CRC) Metastasis: A Nationwide Analysis (2016 to 2020)

Association Between Aspirin Use and Gastric Adenocarcinoma: A Prospective Cohort Study